These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8551786)

  • 1. Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations.
    Sawa Y; Shimazaki Y; Kadoba K; Masai T; Fukuda H; Ohata T; Taniguchi K; Matsuda H
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):29-35. PubMed ID: 8551786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium.
    Sawa Y; Ichikawa H; Kagisaki K; Ohata T; Matsuda H
    J Thorac Cardiovasc Surg; 1998 Sep; 116(3):511-7. PubMed ID: 9731794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury.
    Wan S; Izzat MB; Lee TW; Wan IY; Tang NL; Yim AP
    Ann Thorac Surg; 1999 Jul; 68(1):52-6; discussion 56-7. PubMed ID: 10421114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition.
    Schwertz H; Carter JM; Russ M; Schubert S; Schlitt A; Buerke U; Schmidt M; Hillen H; Werdan K; Buerke M
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):151-60. PubMed ID: 18670364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass.
    Wan S; DeSmet JM; Barvais L; Goldstein M; Vincent JL; LeClerc JL
    J Thorac Cardiovasc Surg; 1996 Sep; 112(3):806-11. PubMed ID: 8800171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
    Usui A; Hiroura M; Kawamura M; Hibi M; Yoshida K; Murakami F; Tomita Y; Ooshima H; Murase M
    Ann Thorac Surg; 1996 Nov; 62(5):1404-11. PubMed ID: 8893576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiopulmonary bypass-induced inflammation: is it important?
    Hill GE
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):21-5. PubMed ID: 9583572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass.
    Schulze CJ; Castro MM; Kandasamy AD; Cena J; Bryden C; Wang SH; Koshal A; Tsuyuki RT; Finegan BA; Schulz R
    Crit Care Med; 2013 Nov; 41(11):2512-20. PubMed ID: 23928836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction.
    Nakanishi K; Takeda S; Sakamoto A; Kitamura A
    Crit Care Med; 2006 May; 34(5):1351-7. PubMed ID: 16540949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normoxic cardiopulmonary bypass reduces oxidative myocardial damage and nitric oxide during cardiac operations in the adult.
    Ihnken K; Winkler A; Schlensak C; Sarai K; Neidhart G; Unkelbach U; Mülsch A; Sewell A
    J Thorac Cardiovasc Surg; 1998 Aug; 116(2):327-34. PubMed ID: 9699587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep hypothermic circulatory arrest and global reperfusion injury: avoidance by making a pump prime reperfusate--a new concept.
    Allen BS; Veluz JS; Buckberg GD; Aeberhard E; Ignarro LJ
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):625-32. PubMed ID: 12658205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-pump, beating-heart coronary artery operations in high-risk patients: an acceptable trade-off?
    Perrault LP; Menasché P; Peynet J; Faris B; Bel A; de Chaumaray T; Gatecel C; Touchot B; Bloch G; Moalic JM
    Ann Thorac Surg; 1997 Nov; 64(5):1368-73. PubMed ID: 9386706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization.
    Hennein HA; Ebba H; Rodriguez JL; Merrick SH; Keith FM; Bronstein MH; Leung JM; Mangano DT; Greenfield LJ; Rankin JS
    J Thorac Cardiovasc Surg; 1994 Oct; 108(4):626-35. PubMed ID: 7934095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury.
    Kawamura T; Wakusawa R; Okada K; Inada S
    Can J Anaesth; 1993 Nov; 40(11):1016-21. PubMed ID: 8269560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of N-acetylcysteine in attenuating ischemic reperfusion injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.
    Prabhu A; Sujatha DI; Kanagarajan N; Vijayalakshmi MA; Ninan B
    Ann Vasc Surg; 2009; 23(5):645-51. PubMed ID: 19467834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginsenosides compound (shen-fu) attenuates gastrointestinal injury and inhibits inflammatory response after cardiopulmonary bypass in patients with congenital heart disease.
    Xia ZY; Liu XY; Zhan LY; He YH; Luo T; Xia Z
    J Thorac Cardiovasc Surg; 2005 Aug; 130(2):258-64. PubMed ID: 16077384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10.
    Giomarelli P; Scolletta S; Borrelli E; Biagioli B
    Ann Thorac Surg; 2003 Jul; 76(1):117-23. PubMed ID: 12842524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass.
    Prondzinsky R; Knüpfer A; Loppnow H; Redling F; Lehmann DW; Stabenow I; Witthaut R; Unverzagt S; Radke J; Zerkowski HR; Werdan K
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):760-6. PubMed ID: 15821641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage.
    Wendel HP; Heller W; Michel J; Mayer G; Ochsenfahrt C; Graeter U; Schulze J; Hoffmeister HM; Hoffmeister HE
    J Thorac Cardiovasc Surg; 1995 Jun; 109(6):1164-72. PubMed ID: 7539874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.